-- Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN) --
-- Potential of CCR2 Inhibitor as a Therapeutic Treatment Option for FSGS Validated --
"The findings presented at ERA-EDTA illustrate the value of our chemoattractant inhibitor platform in the treatment of kidney disease," said Thomas
Decrease in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN)
This open-label pilot Phase II trial in
"To see such a benefit on proteinuria, a key marker for IgA Nephropathy, on top of a maximum tolerated dose of a RAAS inhibitor, was quite encouraging," said Annette Bruchfeld, M.D., Ph.D., from the
Potential of CCR2 Inhibition as a Therapeutic Treatment Option for Focal Segmental Glomerulosclerosis (FSGS)
In an oral presentation on
Researchers concluded that blocking CCR2 provides marked and rapid renal protection in two distinct models of FSGS, as measured by reduction in proteinuria and improvement in multiple histological parameters, and thus represents a novel and mechanistically distinct approach for the treatment of FSGS. The study support ChemoCentryx's plans to conduct a clinical endpoint study with CCR2 inhibitor CCX140 for FSGS, which has already been shown to have good safety and tolerability in hundreds of patients in clinical trials completed to date.
Abstracts of both studies can be found in the
About Avacopan (CCX168)
Avacopan (CCX168) is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while successfully allowing elimination of high-dose steroids, part of the standard of care for AAV patients. Avacopan is also being developed in patients with atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). In C3G, Avacopan targets the C5a receptor, blocking the effects of C5a which contributes to the inflammatory hypercellularity in the glomeruli, a main feature of C3G
The U.S. Food and Drug Administration has now granted avacopan orphan-drug designation for all three of these diseases: C3G, AAV, and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of AAV: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and C3G.
Avacopan was also granted access to the
ChemoCentryx also has an immuno-oncology program, which includes a distinct CCR2 inhibitor, CCX872, currently in development for the treatment of advanced non-resectable pancreatic cancer.
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements whether avacopan (CCX168) will be shown to be safe and effective in the treatment of IgA nephropathy and other rare diseases, whether CCX140 will be shown to be safe and effective in the treatment of focal segmental glomerulosclerosis (FSGS) and the Company's statement regarding the timing of initiating additional clinical trials to further investigate CCX140 in the treatment of FSGS. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC March 14, 2017 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Susan M. KanayaExecutive Vice President, Finance and Chief Financial and Administrative Officer firstname.lastname@example.org Media: Denise Powelldenise@redhousecomms.com 510.703.9491 Investors: Steve Klass, Burns McClellan212.213.0006 email@example.com
News Provided by Acquire Media